• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植患者中巨细胞病毒相关结局指标的普遍预防与抢先治疗方法的比较:现有数据的荟萃分析

Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated outcome measures in renal transplant patients: A meta-analysis of available data.

作者信息

Caskurlu Hulya, Karadag Fatma Y, Arslan Ferhat, Cag Yasemin, Vahaboglu Haluk

机构信息

Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, Istanbul Medeniyet Universitesi, Istanbul, Turkey.

出版信息

Transpl Infect Dis. 2019 Feb;21(1):e13016. doi: 10.1111/tid.13016. Epub 2018 Nov 9.

DOI:10.1111/tid.13016
PMID:30358045
Abstract

Cytomegalovirus (CMV) is a ubiquitous latent human virus that often causes complications in renal transplantation recipients. Universal prophylaxis and preemptive therapy are alternative strategies to prevent CMV associated complications. This meta-analysis aimed to assess available data comparing the effectiveness of prophylaxis and preemptive therapy for preventing adverse outcomes. We searched the PubMed, Ovid, Web of Science, Cochrane Library, and Open Grey databases using a combination of keywords. Random effects models along with the Paule-Mandel estimator were used to synthesize pooled effect estimates. Eleven studies were eligible for the final analysis. Universal prophylaxis was better at preventing CMV disease than the preemptive approach (risk difference = -0.0459; confidence intervals = -0.0791, -0.0127; P-value = 0.0067; number needed to treat [NNT] = 22 [1/0.0459]; high, 79 [1/0.0127] patients; low, 13 [1/0.0791] patients). Subgroup analysis revealed a more consistent effect among studies published after 2010, with negligible between-study heterogeneity. The NNT for universal prophylaxis to prevent one excess CMV disease concerning preemptive therapy was 16 (1/0.0630) patients (high, 25 [1/0.0394]; low, 12 [1/0.0867] patients) in the subgroup of studies performed after 2010. We detected no significant difference between the two strategies regarding acute rejection and graft loss, with negligible variability due to heterogeneity between studies. Although universal prophylaxis performed better than the preemptive strategy for the prevention of CMV disease, the high NNT value may discourage the use of CMV prophylaxis. Since there were no differences between the strategies concerning acute rejection and graft loss, this study supports the use of the preemptive approach as an alternative to universal prophylaxis.

摘要

巨细胞病毒(CMV)是一种普遍存在的人类潜伏病毒,常导致肾移植受者出现并发症。普遍预防和抢先治疗是预防CMV相关并发症的替代策略。这项荟萃分析旨在评估比较预防和抢先治疗预防不良结局有效性的现有数据。我们使用关键词组合在PubMed、Ovid、科学网、Cochrane图书馆和Open Grey数据库中进行了检索。采用随机效应模型和Paule-Mandel估计量来综合合并效应估计值。11项研究符合最终分析的条件。普遍预防在预防CMV疾病方面比抢先治疗更好(风险差=-0.0459;置信区间=-0.0791,-0.0127;P值=0.0067;需治疗人数[NNT]=22[1/0.0459];高值,79[1/0.0127]名患者;低值,13[1/0.0791]名患者)。亚组分析显示,2010年后发表的研究中效果更为一致,研究间异质性可忽略不计。在2010年后进行的研究亚组中,普遍预防相对于抢先治疗预防一例额外CMV疾病的NNT为16(1/0.0630)名患者(高值,25[1/0.0394];低值,12[1/0.0867]名患者)。我们发现两种策略在急性排斥反应和移植物丢失方面无显著差异,研究间异质性导致的变异性可忽略不计。虽然普遍预防在预防CMV疾病方面比抢先策略更好,但高NNT值可能会阻碍CMV预防的使用。由于两种策略在急性排斥反应和移植物丢失方面没有差异,本研究支持将抢先治疗作为普遍预防的替代方法。

相似文献

1
Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated outcome measures in renal transplant patients: A meta-analysis of available data.肾移植患者中巨细胞病毒相关结局指标的普遍预防与抢先治疗方法的比较:现有数据的荟萃分析
Transpl Infect Dis. 2019 Feb;21(1):e13016. doi: 10.1111/tid.13016. Epub 2018 Nov 9.
2
[Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].更昔洛韦抢先治疗对肾移植受者发生巨细胞病毒病高风险(R-/D+)的有效性
Rev Invest Clin. 2002 May-Jun;54(3):198-203.
3
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.抢先治疗与抗病毒预防对供体血清阳性受者血清阴性肝移植患者巨细胞病毒病的影响:一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138.
4
Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.对高风险(供体巨细胞病毒血清学阳性、受体巨细胞病毒血清学阴性)肾移植受者进行抢先抗巨细胞病毒治疗。
Int J Infect Dis. 2017 Dec;65:50-56. doi: 10.1016/j.ijid.2017.09.023. Epub 2017 Oct 3.
5
Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.重新评估巨细胞病毒感染在肾移植和肾胰联合移植中的影响。
Am J Kidney Dis. 2002 May;39(5):1088-95. doi: 10.1053/ajkd.2002.32793.
6
Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.实体器官移植受者中,更昔洛韦抢先治疗与普遍预防巨细胞病毒感染的比较。
Clin Infect Dis. 2001 Mar 1;32(5):742-51. doi: 10.1086/319225. Epub 2001 Feb 20.
7
Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.接受抗胸腺细胞球蛋白诱导治疗的血清学阳性肾移植受者的巨细胞病毒预防:晚期巨细胞病毒疾病的结局和危险因素。
Transpl Infect Dis. 2018 Oct;20(5):e12929. doi: 10.1111/tid.12929. Epub 2018 Jul 2.
8
Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.现代免疫抑制下肾移植中的巨细胞病毒危险因素
Transpl Infect Dis. 2010 Dec;12(6):480-8. doi: 10.1111/j.1399-3062.2010.00533.x.
9
Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. preemptive 与序贯预防性-抢先治疗方案在肾移植中治疗巨细胞病毒:治疗失败和抗病毒耐药的比较。
Transplantation. 2010 Feb 15;89(3):320-6. doi: 10.1097/TP.0b013e3181bc0301.
10
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.荟萃分析:巨细胞病毒预防实体器官移植受者器官疾病策略的疗效
Ann Intern Med. 2005 Dec 20;143(12):870-80. doi: 10.7326/0003-4819-143-12-200512200-00005.

引用本文的文献

1
Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study.缬更昔洛韦预防在低剂量利妥昔单抗诱导治疗后的肾移植受者中的疗效:一项多中心回顾性研究。
Clin Exp Nephrol. 2025 Mar;29(3):359-367. doi: 10.1007/s10157-024-02578-4. Epub 2024 Oct 25.
2
Management of cytomegalovirus infection after liver transplantation.肝移植术后巨细胞病毒感染的管理
World J Transplant. 2024 Sep 18;14(3):93209. doi: 10.5500/wjt.v14.i3.93209.
3
The pattern of cytomegalovirus replication in post-renal transplant recipients with pre-emptive therapy strategy during the 1 year of post-transplantation.
肾移植术后采用抢先治疗策略的患者在移植后1年内巨细胞病毒的复制模式。
Int J Health Sci (Qassim). 2023 Sep-Oct;17(5):39-44.
4
A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients.优化巨细胞病毒抢先治疗与抗病毒预防用于预防巨细胞病毒高风险(D+R-)肾移植受者巨细胞病毒病的系统评价与荟萃分析
Transplant Direct. 2023 Jul 12;9(8):e1514. doi: 10.1097/TXD.0000000000001514. eCollection 2023 Aug.
5
Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis.常规抗病毒药物在肾移植后巨细胞病毒感染预防策略中的疗效和安全性:系统评价和网络荟萃分析。
Transpl Int. 2021 Dec;34(12):2720-2734. doi: 10.1111/tri.14122. Epub 2021 Oct 28.
6
Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.年龄很重要:CMV 血清阳性的肾移植受者中,年龄较大是 CMV 再激活的危险因素。
Eur J Clin Microbiol Infect Dis. 2020 Mar;39(3):455-463. doi: 10.1007/s10096-019-03744-3. Epub 2019 Nov 22.
7
[Benefits and risks of early versus late ureteric stent removal after kidney transplantation].肾移植术后早期与晚期拔除输尿管支架的益处与风险
Urologe A. 2019 Feb;58(2):168-171. doi: 10.1007/s00120-019-0856-y.